TY - JOUR
T1 - Personalization of Pharmacological Treatments for ADHD
T2 - Why it is Advisable and Possible Options to Achieve it
AU - Herrera-Morales, Wendy Verónica
AU - Ramírez-Lugo, Leticia
AU - Cauich-Kumul, Roger
AU - Murillo-Rodríguez, Eric
AU - Núñez-Jaramillo, Luis
N1 - Publisher Copyright:
© 2022 Bentham Science Publisher.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Attention-deficit hyperactivity disorder is a neurodevelopmental disorder diagnosed pri-marily in children, although it is also present in adults. Patients present inattention, impulsivity, and hyperactivity symptoms that create difficulties in their daily lives. Pharmacological treatment with stimulants or non-stimulants is used most commonly to reduce ADHD symptoms. Although gener-ally effective and safe, pharmacological treatments have different effects among patients, including lack of response and adverse reactions. The reasons for these differences are not fully understood, but they may derive from the highly diverse etiology of ADHD. Strategies to guide optimal pharmacological treatment selection based on individual patients’ physiological markers are being de-veloped. In this review, we describe the main pharmacological ADHD treatments used and their main drawbacks. We present alternatives under study that would allow the customization of pharmacological treatments to overcome these drawbacks and achieve more reliable improvement of ADHD symptoms.
AB - Attention-deficit hyperactivity disorder is a neurodevelopmental disorder diagnosed pri-marily in children, although it is also present in adults. Patients present inattention, impulsivity, and hyperactivity symptoms that create difficulties in their daily lives. Pharmacological treatment with stimulants or non-stimulants is used most commonly to reduce ADHD symptoms. Although gener-ally effective and safe, pharmacological treatments have different effects among patients, including lack of response and adverse reactions. The reasons for these differences are not fully understood, but they may derive from the highly diverse etiology of ADHD. Strategies to guide optimal pharmacological treatment selection based on individual patients’ physiological markers are being de-veloped. In this review, we describe the main pharmacological ADHD treatments used and their main drawbacks. We present alternatives under study that would allow the customization of pharmacological treatments to overcome these drawbacks and achieve more reliable improvement of ADHD symptoms.
KW - ADHD
KW - Adverse reaction
KW - Atomoxetine
KW - Methylphenidate
KW - Non-responder
KW - Treatment personalization
KW - qEEG-guided drug selection
UR - http://www.scopus.com/inward/record.url?scp=85135165527&partnerID=8YFLogxK
U2 - 10.2174/1568026622666220509155413
DO - 10.2174/1568026622666220509155413
M3 - Estudio breve
C2 - 35579123
AN - SCOPUS:85135165527
SN - 1568-0266
VL - 22
SP - 1236
EP - 1249
JO - Current Topics in Medicinal Chemistry
JF - Current Topics in Medicinal Chemistry
IS - 15
ER -